ISIS 2302-CS22, A 6-Week, Active-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis
Completed
Ionis Pharmaceuticals, Inc.
Phase 2
1969-12-31
This is a multi-center trial to test the safety, efficacy and tolerability of alicaforsen
(ISIS 2302), a new type of drug called an antisense drug, in patients with mild to moderate
active Ulcerative Colitis (UC). Alicaforsen is designed to reduce the production of a
specific protein, called ICAM-1, a substance that plays a significant role in the increase of
inflammation and is likely to be involved in inflammatory bowel diseases such as ulcerative
colitis. The ISIS 2302-CS22 study will examine the effects of one of two dosages of
alicaforsen delivered by enema over a six-week period as compared to an active control,
mesalamine enema (The probability of receiving the alicaforsen formulation is 2:1). The
primary objective of this study is to evaluate the percentage reduction in DAI at Week 6.
Imuran (Azathioprine) Dose-Ranging Study in Crohn's Disease
Terminated
Massachusetts General Hospital
Phase 3
2005-04-01
The purpose of this study is to identify an optimal weight based dose of azathioprine that is
safe and effective in the treatment of subjects with active Crohn's disease requiring
treatment with corticosteroids, and for maintaining remission in those subjects.
Trial of Growth Hormone Therapy in Pediatric Crohn's Disease
Completed
Genentech, Inc.
Phase 2
2005-04-01
The purpose of this study is to determine whether taking a growth hormone (GH) drug called
somatropin causes the intestine of a person with Crohn's Disease (CD) to heal faster when
compared to a person with Crohn's Disease that does not receive growth hormone drug.
Trial of Growth Hormone Therapy in Pediatric Crohn's Disease
Completed
Children's Hospital Medical Center, Cincinnati
Phase 2
2005-04-01
The purpose of this study is to determine whether taking a growth hormone (GH) drug called
somatropin causes the intestine of a person with Crohn's Disease (CD) to heal faster when
compared to a person with Crohn's Disease that does not receive growth hormone drug.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
